Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18757727 | COPPER NANOCLUSTERS, COMPOSITION COMPRISING THE SAME, AND TREATMENT OF MULTIPLE SCLEROSIS | June 2024 | August 2025 | Allow | 14 | 1 | 0 | No | No |
| 17926004 | TARGETED ANTIVIRAL DRUGS | June 2023 | February 2026 | Abandon | 39 | 1 | 0 | No | No |
| 18004973 | LIPOSOMAL OZONE NANOSOLUTIONS | January 2023 | October 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18078694 | CATHETER LOCK SOLUTIONS INCORPORATING NITRIC OXIDE RELEASING LIPOSOMES | December 2022 | January 2026 | Abandon | 37 | 1 | 0 | No | No |
| 17994196 | SUSTAINED-RELEASE PHEROMONE PREPARATION | November 2022 | March 2026 | Allow | 39 | 3 | 0 | Yes | No |
| 17998589 | PEG LIPIDOID COMPOUNDS | November 2022 | August 2025 | Allow | 34 | 1 | 0 | No | No |
| 17934198 | OROMUCOSAL FILM COMPOSITIONS | September 2022 | September 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17946067 | SKIN CREAM FOR REDUCING BED SORES | September 2022 | July 2025 | Abandon | 34 | 2 | 0 | Yes | No |
| 17929630 | SURFACTANT VESICLES FOR VACCINE FORMULATION, TARGETED DRUG DELIVERY, AND TRANSFECTION | September 2022 | September 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17802655 | PREPARATION FOR MAGNETIZING KIDNEY STONES AND KIDNEY STONE FRAGMENTS AND KIT FOR REMOVING KIDNEY STONES AND KIDNEY STONE FRAGMENTS | August 2022 | July 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17783814 | Antimicrobial Composition | June 2022 | July 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17767816 | DELIVERY SYSTEM COMPLEXES COMPRISING A PRECIPITATE OF AN ACTIVE AGENT AND METHODS OF USE | April 2022 | July 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17700950 | Cryoprotective Compositions, Surgical Kits, and Methods for Protection of a Surgical Site During Cryosurgery | March 2022 | June 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17631525 | PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONS | January 2022 | January 2026 | Allow | 47 | 2 | 0 | Yes | No |
| 17645509 | PHARMACEUTICAL COMPOSITION | December 2021 | September 2025 | Abandon | 45 | 4 | 0 | Yes | No |
| 17618638 | ACTIVE SUBSTANCE DELIVERY SYSTEM | December 2021 | October 2025 | Abandon | 46 | 3 | 0 | No | No |
| 17457793 | LIPID COMPOSITION | December 2021 | July 2025 | Allow | 43 | 3 | 0 | Yes | No |
| 17595083 | HIGH SPREADING AND UPTAKE ULV FORMULATIONS | November 2021 | November 2025 | Abandon | 48 | 3 | 0 | No | No |
| 17608776 | COSMETIC COMPOSITIONS FOR SOFT-FOCUS | November 2021 | July 2025 | Abandon | 44 | 2 | 0 | No | No |
| 16606291 | SURFACE-HYDROPHOBICIZED CELLULOSE NANOFIBERS FOR OILY THICKENER, OILY THICKENER COMPOSITION CONTAINING SAME, COSMETICS AND HYDROPHOBICIZED CELLULOSE NANOFIBER COMPLEX FOR OILY THICKENER CONTAINING SAME, OILY THICKENER COMPOSITION CONTAINING SAME, AND COSMETICS CONTAINING SAME | October 2021 | May 2025 | Allow | 60 | 3 | 0 | Yes | No |
| 16982060 | PAENIBACILLUS STRAIN CAPABLE OF PRODUCING POLYSACCHARIDES WITH AFTER-SUN REPAIR EFFECT AND USE THEREOF | October 2021 | February 2025 | Allow | 53 | 2 | 0 | Yes | No |
| 17606023 | INJECTABLE SUSTAINED-RELEASE FORMULATIONS FOR TREATMENT OF JOINT PAIN AND INFLAMMATION | October 2021 | February 2026 | Allow | 52 | 3 | 0 | No | No |
| 17602327 | CHLORHEXIDINE SYSTEMS AND METHODS FOR OBTAINING SAME | October 2021 | January 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17482898 | Cryoprotective Compositions and Methods for Protection of a Surgical Site During Cryosurgery | September 2021 | July 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17593714 | NON-THERAPEUTIC COSMETIC USE OF CARBOXYALKYLATED STARCH IN AN EMULSION FOR CUSHION AND SOFT FEEL SENSORY EFFECTS | September 2021 | January 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17441416 | THERAPY FOR COLORECTAL AND SMALL INTESTINE CANCERS | September 2021 | January 2026 | Allow | 52 | 3 | 0 | No | No |
| 17439348 | IN SITU GEL-FORMING DELIVERY SYSTEMS, METHODS AND COMPOSITIONS | September 2021 | August 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17435879 | COSMETIC OR PERSONAL CARE FORMULATIONS CONTAINING POROUS METAL OXIDE SPHERES | September 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17433534 | Fatty Acid Derivatives For Improving The Effect Of Agrochemical Actives | August 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17430119 | BIOMATERIALS COMPRISING A SCAFFOLD CONTAINING A MINERAL COMPOUND, AND USES THEREOF AS BONE SUBSTITUTES | August 2021 | January 2026 | Abandon | 53 | 4 | 0 | No | No |
| 17426864 | INSTANTLY SOLUBLE PARTICLE AND METHOD FOR PRODUCING THE SAME | July 2021 | March 2025 | Abandon | 44 | 2 | 0 | Yes | No |
| 17425294 | DRUG AND PRODUCTION METHOD THEREFOR | July 2021 | February 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17423301 | PLANT GROWTH REGULATING AGENT | July 2021 | October 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17422803 | MULTILAYERED CATIONIC LIPOSOME FOR ENHANCING SKIN ABSORPTION AND PREPARATION METHOD THEREFOR | July 2021 | January 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17267927 | OIL-IN-WATER EMULSION COSMETIC COMPOSITION | July 2021 | January 2026 | Abandon | 59 | 4 | 0 | No | No |
| 17417261 | ANTIMICROBIAL AGENT INCLUDING SiOx NANOPARTICLES AND METHOD OF PREPARING ANTIMICROBIAL AGENT | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17309744 | COPPER NANOCLUSTERS, COMPOSITION COMPRISING THE SAME, AND TREATMENT OF MULTIPLE SCLEROSIS | June 2021 | May 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17309565 | EMULSIFYING COMPOSITION CONSISTING OF AN OIL-IN-WATER EMULSIFIER AND A CYCLODEXTRIN OF SELECTED PARTICLE SIZE, CAPABLE OF PROVIDING AN OIL-IN-WATER EMULSION WITH IMPROVED SENSORY EFFECTS FOR COSMETIC USE | June 2021 | June 2025 | Abandon | 49 | 3 | 0 | No | No |
| 17291960 | LIPID NANOPARTICLE FORMULATIONS | May 2021 | September 2025 | Abandon | 52 | 2 | 0 | No | Yes |
| 17289807 | FERRITIN NANOPARTICLES COMPRISING A CHEMOTHERAPEUTIC AGENT | April 2021 | August 2025 | Abandon | 51 | 5 | 0 | No | No |
| 17288440 | FRAGRANCE BLENDS AND METHODS FOR PREPARATION THEREOF | April 2021 | December 2025 | Abandon | 55 | 4 | 0 | No | No |
| 17286293 | DRY PHARMACEUTICAL COMPOSITION FOR INHALATION | April 2021 | December 2024 | Abandon | 44 | 2 | 0 | Yes | No |
| 17260640 | TRIBLOCK COPOLYMER STABILIZERS FOR THE FORMATION OF NANOPARTICLES ENCAPSULATING SOLUBLE BIOLOGICS, THERAPEUTICS, AND IMAGING AGENTS | January 2021 | March 2024 | Allow | 38 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NGUYEN, NGOC-ANH THI.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NGUYEN, NGOC-ANH THI works in Art Unit 1615 and has examined 29 patent applications in our dataset. With an allowance rate of 27.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner NGUYEN, NGOC-ANH THI's allowance rate of 27.6% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NGUYEN, NGOC-ANH THI receive 2.34 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by NGUYEN, NGOC-ANH THI is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +56.7% benefit to allowance rate for applications examined by NGUYEN, NGOC-ANH THI. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.1% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 36.4% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.